Adolescent Smoking Cessation With Bupropion: The Role of Adherence

Scott J. Leischow, Myra L. Muramoto, Eva Matthews, Lysbeth L. Floden, Rachel A. Grana

Research output: Research - peer-reviewArticle

  • 3 Citations

Abstract

Introduction: While many medications can be effective aids to quitting tobacco, real world adherence to smoking cessation medications may render a potentially effective medication ineffective. The present study investigated the role of adherence on treatment outcomes in a bupropion doseresponse study among adolescent smokers trying to quit smoking. Methods: Three hundred twelve adolescent boys (n = 143) and girls (n = 169) between the ages of 14-17 were enrolled in the study, and were randomly assigned to use either 300 mg, 150 mg or placebo bupropion to quit smoking. Among the eligibility criterion, participants had to smoke at least six cigarettes per day, be motivated to quit smoking (self report), have an exhaled carbon monoxide level greater than or equal to 10 ppm, and report at least two previous quit attempts. Adherence to medication was determined by both self-report and actual counts of unused medication and empty medication packaging. Smoking status was determined by a combination of self-report and biochemical verification (breath carbon monoxide and urine cotinine). Results: Cotinine-confirmed quit rates were significantly higher as a function of high adherence (20.69%) relative to low adherence (0.00%) in the 300-mg Bupropion Sustained Release group. Overall adherence in all study conditions in this highly controlled study was high (74%), but was significantly lower in non-white participants. Conclusions: Effectiveness of bupropion for adolescent smoking cessation is contingent on achieving high rates of medication adherence, but considerable variations in adherence impacted outcomes. Implications: Few studies have assessed the safety and efficacy of medications to help adolescent smokers quit, and we conducted one such study assessing bupropion. In this analysis of that original study, we assess the role of adherence in use of medication and quit rates. We found that adherence was related to outcomes, particularly in the 300-mg dose of bupropion.

LanguageEnglish (US)
Article numberntv144
Pages1202-1205
Number of pages4
JournalNicotine and Tobacco Research
Volume18
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Bupropion
Smoking Cessation
Smoking
Self Report
Cotinine
Medication Adherence
Carbon Monoxide
Product Packaging
Smoke
Tobacco Products
Tobacco
Placebos
Urine
Safety

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Leischow, S. J., Muramoto, M. L., Matthews, E., Floden, L. L., & Grana, R. A. (2016). Adolescent Smoking Cessation With Bupropion: The Role of Adherence. Nicotine and Tobacco Research, 18(5), 1202-1205. [ntv144]. DOI: 10.1093/ntr/ntv179

Adolescent Smoking Cessation With Bupropion : The Role of Adherence. / Leischow, Scott J.; Muramoto, Myra L.; Matthews, Eva; Floden, Lysbeth L.; Grana, Rachel A.

In: Nicotine and Tobacco Research, Vol. 18, No. 5, ntv144, 01.05.2016, p. 1202-1205.

Research output: Research - peer-reviewArticle

Leischow, SJ, Muramoto, ML, Matthews, E, Floden, LL & Grana, RA 2016, 'Adolescent Smoking Cessation With Bupropion: The Role of Adherence' Nicotine and Tobacco Research, vol 18, no. 5, ntv144, pp. 1202-1205. DOI: 10.1093/ntr/ntv179
Leischow SJ, Muramoto ML, Matthews E, Floden LL, Grana RA. Adolescent Smoking Cessation With Bupropion: The Role of Adherence. Nicotine and Tobacco Research. 2016 May 1;18(5):1202-1205. ntv144. Available from, DOI: 10.1093/ntr/ntv179
Leischow, Scott J. ; Muramoto, Myra L. ; Matthews, Eva ; Floden, Lysbeth L. ; Grana, Rachel A./ Adolescent Smoking Cessation With Bupropion : The Role of Adherence. In: Nicotine and Tobacco Research. 2016 ; Vol. 18, No. 5. pp. 1202-1205
@article{2697d7bb943b4028919c190bfccb4cdf,
title = "Adolescent Smoking Cessation With Bupropion: The Role of Adherence",
abstract = "Introduction: While many medications can be effective aids to quitting tobacco, real world adherence to smoking cessation medications may render a potentially effective medication ineffective. The present study investigated the role of adherence on treatment outcomes in a bupropion doseresponse study among adolescent smokers trying to quit smoking. Methods: Three hundred twelve adolescent boys (n = 143) and girls (n = 169) between the ages of 14-17 were enrolled in the study, and were randomly assigned to use either 300 mg, 150 mg or placebo bupropion to quit smoking. Among the eligibility criterion, participants had to smoke at least six cigarettes per day, be motivated to quit smoking (self report), have an exhaled carbon monoxide level greater than or equal to 10 ppm, and report at least two previous quit attempts. Adherence to medication was determined by both self-report and actual counts of unused medication and empty medication packaging. Smoking status was determined by a combination of self-report and biochemical verification (breath carbon monoxide and urine cotinine). Results: Cotinine-confirmed quit rates were significantly higher as a function of high adherence (20.69%) relative to low adherence (0.00%) in the 300-mg Bupropion Sustained Release group. Overall adherence in all study conditions in this highly controlled study was high (74%), but was significantly lower in non-white participants. Conclusions: Effectiveness of bupropion for adolescent smoking cessation is contingent on achieving high rates of medication adherence, but considerable variations in adherence impacted outcomes. Implications: Few studies have assessed the safety and efficacy of medications to help adolescent smokers quit, and we conducted one such study assessing bupropion. In this analysis of that original study, we assess the role of adherence in use of medication and quit rates. We found that adherence was related to outcomes, particularly in the 300-mg dose of bupropion.",
author = "Leischow, {Scott J.} and Muramoto, {Myra L.} and Eva Matthews and Floden, {Lysbeth L.} and Grana, {Rachel A.}",
year = "2016",
month = "5",
doi = "10.1093/ntr/ntv179",
volume = "18",
pages = "1202--1205",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Adolescent Smoking Cessation With Bupropion

T2 - Nicotine and Tobacco Research

AU - Leischow,Scott J.

AU - Muramoto,Myra L.

AU - Matthews,Eva

AU - Floden,Lysbeth L.

AU - Grana,Rachel A.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Introduction: While many medications can be effective aids to quitting tobacco, real world adherence to smoking cessation medications may render a potentially effective medication ineffective. The present study investigated the role of adherence on treatment outcomes in a bupropion doseresponse study among adolescent smokers trying to quit smoking. Methods: Three hundred twelve adolescent boys (n = 143) and girls (n = 169) between the ages of 14-17 were enrolled in the study, and were randomly assigned to use either 300 mg, 150 mg or placebo bupropion to quit smoking. Among the eligibility criterion, participants had to smoke at least six cigarettes per day, be motivated to quit smoking (self report), have an exhaled carbon monoxide level greater than or equal to 10 ppm, and report at least two previous quit attempts. Adherence to medication was determined by both self-report and actual counts of unused medication and empty medication packaging. Smoking status was determined by a combination of self-report and biochemical verification (breath carbon monoxide and urine cotinine). Results: Cotinine-confirmed quit rates were significantly higher as a function of high adherence (20.69%) relative to low adherence (0.00%) in the 300-mg Bupropion Sustained Release group. Overall adherence in all study conditions in this highly controlled study was high (74%), but was significantly lower in non-white participants. Conclusions: Effectiveness of bupropion for adolescent smoking cessation is contingent on achieving high rates of medication adherence, but considerable variations in adherence impacted outcomes. Implications: Few studies have assessed the safety and efficacy of medications to help adolescent smokers quit, and we conducted one such study assessing bupropion. In this analysis of that original study, we assess the role of adherence in use of medication and quit rates. We found that adherence was related to outcomes, particularly in the 300-mg dose of bupropion.

AB - Introduction: While many medications can be effective aids to quitting tobacco, real world adherence to smoking cessation medications may render a potentially effective medication ineffective. The present study investigated the role of adherence on treatment outcomes in a bupropion doseresponse study among adolescent smokers trying to quit smoking. Methods: Three hundred twelve adolescent boys (n = 143) and girls (n = 169) between the ages of 14-17 were enrolled in the study, and were randomly assigned to use either 300 mg, 150 mg or placebo bupropion to quit smoking. Among the eligibility criterion, participants had to smoke at least six cigarettes per day, be motivated to quit smoking (self report), have an exhaled carbon monoxide level greater than or equal to 10 ppm, and report at least two previous quit attempts. Adherence to medication was determined by both self-report and actual counts of unused medication and empty medication packaging. Smoking status was determined by a combination of self-report and biochemical verification (breath carbon monoxide and urine cotinine). Results: Cotinine-confirmed quit rates were significantly higher as a function of high adherence (20.69%) relative to low adherence (0.00%) in the 300-mg Bupropion Sustained Release group. Overall adherence in all study conditions in this highly controlled study was high (74%), but was significantly lower in non-white participants. Conclusions: Effectiveness of bupropion for adolescent smoking cessation is contingent on achieving high rates of medication adherence, but considerable variations in adherence impacted outcomes. Implications: Few studies have assessed the safety and efficacy of medications to help adolescent smokers quit, and we conducted one such study assessing bupropion. In this analysis of that original study, we assess the role of adherence in use of medication and quit rates. We found that adherence was related to outcomes, particularly in the 300-mg dose of bupropion.

UR - http://www.scopus.com/inward/record.url?scp=84964978459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964978459&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntv179

DO - 10.1093/ntr/ntv179

M3 - Article

VL - 18

SP - 1202

EP - 1205

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 5

M1 - ntv144

ER -